Results of a small Greek observational study suggest that biosimilar infliximab may be an effective alternative for the treatment of patients with inflammatory bowel disease (IBD) who have active disease and experienced a loss of response to innovator infliximab (Remicade).
Results of a small Greek observational study suggest that biosimilar infliximab may be an effective alternative for the treatment of patients with inflammatory bowel disease (IBD) who have active disease and experienced a loss of response to innovator infliximab (Remicade).
In a Letter to the Editor of Alimentary Pharmacology & Therapeutics, researchers led by Eleni Orfanoudaki, MD, department of gastroenterology, University Hospital of Heraklion, Heraklion, Greece, reported results of a switch to the biosimilar in 15 patients who failed to respond to other biologics, including the reference infliximab. The patients were switched to the biosimilar at 5 mg/kg on weeks 0, 2, 6, and every 8 weeks thereafter.
The researchers noted that although there have been several studies on switching from the reference to the biosimilar in patients whose IBD is in remission, there have been no published results to date on the use of the biosimilar in patients with active disease and a history of loss of response to the reference.
Thus, they reported what they called “unexpected results” with the use of the biosimilar in patients with active IBD and secondary loss of response to innovator infliximab:
There were no available measurements of trough levels and anti-infliximab antibodies, however, and only limited endoscopic data for a few patients. Nonetheless, the results of the small observational study suggest that the biosimilar may be an effective alternative for IBD patients with active disease and loss of response to the reference, the researchers conclude. “The underlying mechanism of action of [the biosimilar] in these cases as well as a further validation of this finding could be assessed by future prospective controlled studies including drug pharmacokinetics," they wrote.
Reference
Orfanoudaki E, Drygiannakis I, Koutroubakis I. Letter: Is there a role for infliximab biosimilar in patients with inflammatory bowel disease with secondary loss of response to infliximab innovator? Aliment Pharmacol Ther.2018. doi:10.1111/apt.14980.
AMCP Posters Tackle Interchangeability and Medicaid, Factors Driving Biosimilar Access
April 24th 2024Two posters from the Academy of Managed Care Pharmacy (AMCP) annual meeting explore how an interchangeable insulin glargine biosimilar plays into Medicaid budgets and the top factors driving access to biosimilars.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Biosimilars Gastroenterology Roundup for January 2024—Podcast Edition
February 4th 2024On this episode of Not So Different, we reminisce on all the major gastroenterology news from January, which brought several reports quantifying how the gastroenterology biosimilar market is progressing and marked the 1-year anniversary of adalimumab biosimilar competition in the US.
What Clinicians Need to Know About Using Biosimilars to Treat IBD
April 13th 2024A review article, intended to act as a guide for clinicians, summarizes the available infliximab and adalimumab biosimilars for treating inflammatory bowel disease (IBD) as well as others that are coming down the pipeline.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.